KalVista Pharmaceuticals, Inc. delivers two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary.

Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA:
KalVista presents data providing the rationale for the sebetralstat regimen for short-term prophylaxis (STP) for medical and dental procedures in people living with HAE in the phase 3 KONFIDENT-S trial, which is an ongoing, up to 2-year, open-label extension of the phase 3 KONFIDENT trial.

HAE Patients Decision to Carry On-demand Treatment When Away from Home: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, ON Canada:
This oral presentation is based on real-world survey data collected from people with HAE and shows that only one-third of patients always carry on-demand attack treatment with them when away from home. Of note, those that did not carry treatment would routinely travel for several hours without it for a variety of reasons, including a preference to treat with injectables at home.

Route of Administration Preferences of People with Hereditary Angioedema for On-demand Treatment: A US-based Qualitative Study: Laurence Bouillet, Internal Medicine, Grenoble Alpes University, National Reference Center for Angioedema, Grenoble, France:
The poster presentation, based on qualitative interviews with adolescents and adults with HAE, demonstrates that both groups had a strong preference for oral medication for on-demand treatment of attacks over self-administered injectable treatments when efficacy and safety profiles were similar.

“The data we have gathered from a comprehensive survey focused on the experience of patients experiencing HAE attacks has been eye-opening and reveals the real-world impact injectable treatments have on the lives of people living with HAE,” says Andrew Crockett, CEO of KalVista. “Strong patient preference data for oral treatments over injectables reflects these challenges. We believe that sebetralstat may have the potential to improve patients’ current treatment experience. Given the challenges with access to and logistics surrounding the use of injectables for short-term prophylaxis prior to routine medical and dental procedures, the oral regimen being assessed in KONFIDENT-S may represent yet another opportunity to enhance the lives of people living with HAE.”
(Source: KalVista)